A role for XRCC2 gene polymorphisms in breast cancer risk and survival by Lin, W.Y. et al.
A role for XRCC2 gene polymorphisms in breast cancer risk and
survival
Wei-Yu Lin1, Nicola J. Camp2, Lisa A. Cannon-Albright2, Kristina Allen-Brady2, Sabapathy
Balasubramanian3, Malcolm W. Reed3, John L. Hopper4, Carmel Apicella4, Graham G
Giles5, Melissa C. Southey6, Roger L. Milne4,7, Jose I.A. Perez8, Primitiva M. Rodríguez8,
Javier Benítez9, Magdalena Grundmann10, Natalia Dubrowinskaja10, Tjoung-Won Park-
Simon10, Thilo Dörk10, Montserrat Garcia-Closas11, Jonine Figueroa12, Mark Sherman12,
Jolanta Lissowska13, Douglas F Easton14,15, Alison M Dunning14,15, Preetha Rajaraman16,
Alice J. Sigurdson16, Michele M. Doody16, Martha S. Linet16, Paul D. Pharoah14,15,
Marjanka K. Schmidt17, and Angela Cox1
1Institute for Cancer Studies, Department of Oncology, University of Sheffield, Sheffield S10 2RX,
UK 2Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah
84108-1266, USA 3Academic Unit of Surgical Oncology, Department of Oncology, University of
Sheffield, Sheffield S10 2RX, UK 4Centre for Molecular Environmental Genetic and Analytical
Epidemiology, School of Population Health, The University of Melbourne, 723 Swanston Street,
Carlton, Victoria 3053, Australia 5Cancer Epidemiology Centre, The Cancer Council Victoria,
Victoria, Australia 6Department of Pathology, The University of Melbourne, Victoria, 3010,
Australia 7Genetic and Molecular Epidemiology Group, Spanish National Cancer Research
Centre (CNIO), Madrid, Spain 8Hospital Monte Naranco, Oviedo, Spain 9Human Genetics Group,
Spanish National Cancer Research Centre (CNIO), Madrid, Spain 10Hannover Medical School,
Clinics of Obstetrics and Gynaecology, Hannover, Germany 11Sections of Epidemiology and
Genetics, Institute of Cancer Research, 15 Cotswold Rd, Belmont Sutton, Surrey SM2 5NG, UK
12Hormonal and Reproductive Epidemiology Branch, National Cancer Institute, 6120 Executive
Blvd., Room 5018, Rockville, MD 20852-7234, USA 13Department of Cancer Epidemiology and
Prevention, The M. Sklodowska-Curie Cancer Center and Institute of Oncology, WH Roentgena
5, 00-782 Warsaw, Poland 14Department of Public Health and Primary Care, University of
Cambridge, Cambridge, UK 15Department of Oncology, University of Cambridge, Cambridge, UK
16Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, U.S. National
Cancer Institute, 6120 Executive Blvd., Rockville, MD 20852, USA 17Netherlands Cancer
Institute, Amsterdam, The Netherlands
Abstract
Background—The XRCC2 gene is a key mediator in the homologous recombination repair of
DNA double strand breaks. We hypothesised that inherited variants in the XRCC2 gene might also
affect susceptibility to, and survival from, breast cancer.
Methods—We genotyped 12 XRCC2 tagging SNPs in 1,131 breast cancer cases and 1,148
controls from the Sheffield Breast Cancer Study (SBCS), and examined their associations with
breast cancer risk and survival by estimating odds ratios (ORs) and hazard ratios (HRs), and their
corresponding 95% confidence intervals (CIs). Positive findings were further investigated in 860
cases and 869 controls from the Utah Breast Cancer Study (UBCS) and jointly analysed together
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with available published data for breast cancer risk. The survival findings were further confirmed
in studies (8,074 cases) from the Breast Cancer Association Consortium (BCAC).
Results—The most significant association with breast cancer risk in the SBCS dataset was the
XRCC2 rs3218408 SNP (recessive model p=2.3×10−4, MAF=0.23). This SNP yielded an ORrec
(95% CI) of 1.64 (1.25–2.16) in a two-site analysis of SBCS and UBCS, and a meta-ORrec (95%
CI) of 1.33 (1.12–1.57) when all published data were included. This SNP may mark a rare risk
haplotype carried by 2 in 1000 of the control population. Furthermore, the XRCC2 coding R188H
SNP (rs3218536, MAF=0.08) was significantly associated with poor survival, with an increased
per-allele HR (95% CI) of 1.58 (1.01–2.49) in a multivariate analysis. This effect was still evident
in a pooled meta-analysis of 8,781 breast cancer patients from the BCAC [HR (95% CI) of 1.19
(1.05–1.36), p=0.01].
Conclusions—Our findings suggest that XRCC2 SNPs may influence breast cancer risk and
survival.
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INTRODUCTION
Homologous recombination repair (HRR) of DNA double strand breaks (DSB) is a crucial
cellular defence system to maintain genomic integrity. Unrepaired or incorrectly repaired
DSB may give rise to chromosome aberrations, such as loss or gain of chromosome
segments and chromosome translocations. These changes might lead to carcinogenesis by
disruption of tumour suppressor genes and activation of proto-oncogenes.[1, 2] The
involvement of the highly penetrant breast cancer genes BRCA1 and BRCA2 in the
homologous recombination repair pathway[3–6] highlights the importance of this
mechanism in breast cancer aetiology.
X-ray repair cross complementing gene-2 (XRCC2) possesses the ATP binding domains
known as Walker motifs A and B, and is one of the RAD51 family of proteins that are
implicated in DNA DSB repair.[7, 8] XRCC2-deficient cells show a greater than 100 fold
reduction in HRR compared to XRCC2-proficient cells,[9] and demonstrate various forms
of chromosomal instability that are often described in breast cancer.[7, 10–12, 8, 13] The
restoration of RAD51 nuclear foci in XRCC2-deficient cells irrespective of RAD51 levels,
[14, 15] and specific binding of XRCC2 to RAD51 family proteins[16] further suggests a
non-redundant role of XRCC2 in normal HRR function. In addition, DNA damage caused
by anticancer drugs and radiation has been documented to require XRCC2 for its repair in
mammalian cells.[17–21] Several lines of evidence demonstrate that high levels of
expression of XRCC3, another member of the RAD51 family of proteins, are associated
with radio- and cytotoxic resistance in human tumour cell lines[22–24] suggesting that
XRCC2 might also be relevant to the effects of tumour treatment.
It has been widely hypothesised that inherited variations in DNA sequence, such as single
nucleotide polymorphisms (SNPs), may modulate DNA repair capacity, thus affecting
individual susceptibility to cancer risk or survival. Earlier investigations concentrated on the
XRCC2 missense SNP rs3218536 (R188H), for its association with breast cancer risk. An
effect of this SNP has been largely ruled out by the Breast Cancer Association Consortium
(BCAC) study,[25] although, due to its low minor allele frequency (MAF), small recessive
effects could not be excluded. More recently, a few gene-based association studies have
been carried out to evaluate XRCC2 SNPs in the context of breast cancer risk.[26–28]
However, only one study examined the XRCC2 SNP associations with breast cancer
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survival.[27] Therefore, we genotyped a comprehensive set of XRCC2 tagging SNPs
(tSNPs) selected from resequencing data and tested the hypotheses that the XRCC2
germline variants captured by the tag SNPs affect breast cancer risk or survival.
METHODS
Study populations
The Sheffield Breast Cancer study (SBCS) formed the discovery set for this study. The
study characteristics and recruitment have been described in detail previously.[29, 30]
Briefly, 1,266 female patients with histologically confirmed breast cancer were recruited
from surgical outpatient clinics at the Royal Hallamshire Hospital, Sheffield and Rotherham
District General Hospital between November 1998 and June 2002. Control subjects
(n=1,270) were drawn from women aged 50–65 years who attended the mammography
breast screening programme in Sheffield between October 2000 and August 2002. The
eligibility criterion for controls was the absence of any evidence of breast malignancy. Study
subjects were all resident in the Sheffield area and of Northern European ancestry. Tumour
characteristics, such as histology, grade, lymph node status, estrogen receptor (ER) and
progesterone receptor (PR) status and tumour size were retrieved by reviewing medical
records and histopathology reports. Follow-up data on vital status was available until
September 2009 through hospital records and the Trent Cancer Registry. All subjects gave
informed consent for the collection of data and blood specimens, and approval for this study
was obtained from South Sheffield Research Ethics Committee.
The Utah breast cancer study (UBCS) was used to replicate the findings in relation to breast
cancer risk. Breast cancer cases (n=860) were drawn from high-risk cancer pedigrees,
identified using a genealogical database (Utah Population Database, UPDB) linked to the
Utah Cancer Registry.[31] Cases known to be due to BRCA1 or BRCA2 mutations were
excluded. Controls (n=869) included unaffected family members and unrelated matched
cancer-free controls. The latter were matched based on sex, birth year (within 5 years) and
birth-place.[32]
Six studies from the BCAC (that had genotype data for XRCC2 R188H, and survival data
available), were employed to verify the XRCC2 SNP associations with survival, including
the Australian Breast Cancer Family Study (ABCFS, n=1,223), the Spanish National Cancer
Centre Breast Cancer study (CNIO-BCS, n=190), the Hannover Breast Cancer Study
(HABCS, n=598), the National Cancer Institute Breast Cancer Study in Poland (PBCS,
n=1,507), Studies of Epidemiology and Risk Factors in Cancer Heredity (SEARCH,
n=4,234) and the US Radiologic Technologist (USRT, n=322) Study.[33, 25] A brief
description of the sources of breast cancer patients and the collection of clinical
characteristics and vital status is given in the Supplementary Materials. Most breast cancer
patients were prevalent cases (supplementary table 1). The majority of tumours were of
ductal type, moderately or well differentiated, with low tumour stage (<=2), no lymph node
involvement, and positive for ER and PR status (supplementary table 2).
Tagging reference panel and selection of tagging SNPs
The Polymorphism Discovery Resource (PDR90) is a mixed-ethnic population of 24
European, 24 African, 12 Mexican, 6 Native and 24 Asian Americans,[34] and has been
used to discover genetic variants by thorough resequencing of all exons, conserved
sequences, and over 1 kb of 5’ upstream and 3’ downstream regions of over 300 genes.[35]
Using 4025 Yoruba-specific SNPs from HapMap Release 22 (i.e. those SNPs known to be
polymorphic in only the Yoruban group), we identified and excluded 22 individuals likely to
be of African genetic background. Data from the remaining 68 subjects (PDR68) were used
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to select tSNPs for the XRCC2 gene. The GERBIL (genotype resolution and block
identification using likelihood) software[36] was used to estimate haplotype frequencies of
61 common SNPs (MAF > 5%) across the XRCC2 gene region in PDR68. Two haplotype
blocks were identified. A minimum allelic r2 of 0.8 within blocks was employed to select
tSNPs using the STATA programme, htSNP2.[37]
Genotyping and quality control
DNA samples were arrayed in 384-well plates, comprising equal numbers of cases and
controls, together with duplicates (~10% of samples). Genotyping was carried out using the
5’ nuclease (TaqMan) and SNPlex multiplex assays (Applied Biosystems, Foster city, CA).
There was no significant deviation of genotype frequencies in controls from those expected
under Hardy-Weinberg equilibrium (HWE) (see supplementary table 3), except for
rs3218455 (empirical p=1×10−4). No obvious clustering errors were found for rs3218455 by
visual inspection of the cluster plots, and this SNP was included in the analysis to maintain
tagging efficiency. Two SNPs were excluded based on a duplicate discordance of over
2.5%. Further to this, any SNP with a call rate of <80%, and any study subjects with > 50%
missing genotypes, were also excluded from analyses. A summary of genotyping quality is
given in supplementary table 3. Among these SNPs there were no differences in genotype
missing rates between cases and controls, except for rs3218534 (p for fisher exact test=0.04,
overall call rate of 95.9%).
Statistical analysis
The χ2 goodness-of-fit test with 1 degree freedom was performed to examine the departure
of genotype frequency from HWE among control subjects, and the empirical significance
value was obtained using Monte Carlo permutation procedures. Associations between the
XRCC2 SNPs and breast cancer risk under specified genetic models were evaluated by
likelihood ratio tests (LRT), using the SNPassoc 1.6–0 package in R 2.90.[38] SNP
associations below the arbitrary Bonferroni threshold for multiple tests of 12 SNPs were
selected for replication. P values shown in the tables are uncorrected for multiple testing.
Haplotype analyses were performed using the SAS PROC HAPLOTYPE routine. Odds
ratios (ORs) and corresponding 95% confidence intervals (CIs) for SNPs and haplotypes
were derived from logistic regression models, with the most common genotype or haplotype
used as the reference. The Genie software was also used to estimate ORs and 95% CIs, in
order to account for the known relatedness amongst Utah subjects.[39, 40] Estimates and
CIs were very consistent between the two methods.
Published data based on a Medline search through April 2010 were incorporated into the
meta-analysis for rs3218408. We also included data from the Cancer Genetic Markers of
Susceptibility (CGEMS, http://cgems.cancer.gov/data/) genome-wide association study
(GWAS) of Hunter et al[41], based on postmenopausal women (1,145 cases and 1,142
controls from the Nurses’ Health Study, NHS). Preliminary analysis showed that OR
estimates obtained from random and fixed effect models were similar, therefore meta-ORs
for tSNPs were estimated and illustrated by forest plots using fixed effect models. The
Cochran Q test and I2[42] were used to examine the homogeneity of ORs across different
centres. All the meta-analyses were performed using the STATA command metan.[43]
For the analysis of associations with survival following breast cancer diagnosis, time at risk
was defined as the interval between date of diagnosis and date of the last follow-up or death.
The heterogeneity of the Kaplan-Meier (K-M) survival functions of genotypes for each SNP
was assessed by the log-rank test. The Cox proportional hazard model was employed to
estimate the hazard ratio (HR) for each tSNP in terms of genotype or alleles, adjusted for
age at diagnosis, and taking into account time between study entry and diagnosis (left
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censoring).[44] Lymph node status (categorical variable), grade (categorical variable) and
tumour size (categorical variable; <=2 cm, 2–5 cm, >5 cm) were included as covariates in
the Cox models for those SNPs with significant associations. Pooled HR estimates were
estimated by including study as a stratification variable. Schoenfeld residuals were used to
assess the assumption of proportional hazards. All significance tests were two-sided and
were performed using the Intercooled STATA 9.2 (College Station, TX), unless otherwise
specified.
RESULTS
XRCC2 SNP associations with breast cancer risk
Twelve XRCC2 tSNPs, including one missense SNP rs3218536 (R188H), were successfully
genotyped in 1,131 cases and 1,148 controls from the SBCS. The mean prediction accuracy
achieved for ungenotyped SNPs based on these tSNPs was > 90%, as assessed in PDR68. Of
the 12 SNPs, 11 were found not to be associated with breast cancer risk under additive,
codominant, dominant or recessive models (figure 1), with all ORs close to unity (see
supplementary table 4). However, we observed statistical evidence of rs3218408 association
with breast cancer risk under the codominant (pLRT=6.7×10−4) and recessive models
(pLRT=2.3×10−4), and both of these p values were below a notional Bonferroni threshold of
4.2×10−3 for 12 SNPs (figure 1). The unadjusted OR for the recessive effect of rs3218408
was 1.92 (1.35–2.75), and remained similar after adjusting for age at diagnosis, age at
menarche, age at first full term pregnancy and family history; 1.85 (1.25–2.72).
Haplotype analyses were performed in the two haplotype blocks as defined in Materials and
Methods. All haplotypes with above 1% frequency were tested individually against the most
common haplotype in the block, and rare haplotypes (frequency < 1%) were grouped
together. In Block 1 (rs3218556, rs3218536, rs3218534, rs3218501, and rs3218499) no
haplotypes were associated with breast cancer risk relative to the most common haplotype
(table 1). In Block 2 (rs3218455, rs3111465, rs3094406, rs3218408, rs3218400, rs2106776,
and rs3218374), the combined group of rare haplotypes were associated with increased risk
relative to the most common haplotype with an estimated OR (95% CI) of 1.68 (1.21–2.32)
(table 1). On closer inspection, the inflated risk was primarily due to one rare haplotype that
included the minor allele of rs3218408, together with the minor allele at rs3218374
(frequency of 0.89% in cases and 0.20% in controls),which was associated with an OR (95%
CI) of 6.50 (1.88–22.48). This suggests that this very rare haplotype may harbour one or
more susceptibility loci (table 1).
To confirm the single SNP finding for rs3218408, we genotyped it in 860 cases and 869
controls from the UBCS. The MAF of the G allele in UBCS controls was similar to that seen
in the SBCS controls, 0.21 compared to 0.23 (supplementary table 3), and genotype
frequencies were consistent with HWE (pHWE=0.98). There was evidence of association
between rs3218408 and breast cancer risk in the UBCS, although the inheritance pattern was
more consistent with the additive and dominant models, in contrast to the codominant and
recessive models that were indicated in the SBCS dataset (figure 2). However, there was no
evidence of heterogeneity between studies for any model (phet=0.17–0.45 and I2=0%-46.6%;
data not shown). In a joint analysis of the SBCS and UBCS, SNP rs3218408 showed
statistically significant association with the susceptibility to breast cancer in the additive,
recessive, and codominant models, with ORs (95% CIs) of 1.16 (1.04–1.29) [p=6×10−3] per
G allele, 1.64 (1.25–2.16) [p=3.31×10−4] under a recessive model and 1.66 (1.26–2.19)
[p=3.18×10−4] for homozygosity of the minor allele. To further validate this finding, we
extended the analysis to include publicly available data for rs3218408. These included data
from Han et al[28] based on premenopausal women from the NHS and from the CGEMs
GWAS of Hunter et al[41] based on postmenopausal women from the NHS. In addition, we
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included data from the SEARCH study on the SNP rs3218499,[45] which is in high LD with
rs3218408 (r2=0.97 in our controls). All five studies consistently demonstrated a risk effect
for the rare homozygotes, with meta-OR (95% CI) for the recessive model of 1.33 (1.12–
1.57) [p=0.001] (figure 2) in a sample size of 5,518 cases and 5,890 controls.
XRCC2 SNP associations with survival of breast cancer patients
Vital status post-diagnosis was available for 814 of the 1,131 SBCS breast cancer cases. The
median follow-up was 11.12 years (range 0.98–40.59). Many of the cases were prevalent
cases, with a mean of 4.05 and a median of 2.85 years between diagnosis and recruitment to
the study. Table 2 summarises the survival data by SNP. There were statistically significant
differences in the K-M survival functions among genotypes for rs3218536 (p=4×10−6),
rs3218534 (p=0.0224), rs3218455 (p=2×10−6) and rs3218374 (p=0.0248), with the p values
for rs3218536 and rs3218455 being below a Bonferroni correction threshold of 4.2×10−3 for
12 SNPs. After adjustment for age and accounting for left-censoring time, the adjusted HRs
[aHRs (95% CIs)] of the homozygous minor allele genotypes were 4.26 (1.69–10.72) and
3.86 (1.76–8.47) for rs3218536 and rs3218455, respectively, whilst both rs3218534 and
rs3218374 heterozygous genotypes had about 40% reduction in aHRs, compared to the
homozygous genotypes for the common allele. There were allele-dosage effects for both
rs3218536 and rs3218455, with aHRs (95% CIs) of 1.48 (1.04–2.13) [p=0.032] for
rs3218536 and 1.51 (1.08–2.10) [p=0.016] for rs3218455 (table 2). The assumption of
proportionality of the baseline hazards was valid for both SNPs (p>0.05). These two SNPs
are correlated (r2=0.85) and thus are likely to reflect the same underlying effect. The
rs3218536 SNP, which causes the amino acid substitution R188H, was included in a model
that further adjusted for lymph node status, grade and tumour size. The minor A allele was
significantly associated with poor survival, with a aHR (95% CI) of 1.58 (1.01–2.49)
[p=0.046].
We tested for replication of the rs3218536 association with survival in six studies from the
BCAC, for which genotype data for rs3218536 and survival data were available. The
distribution of age at diagnosis, time from diagnosis to recruitment, follow-up time, and
available clinical characteristics for each study are shown in supplementary tables 1 and 2.
Table 3 shows a summary of the HR estimates associated with rs3218536 by study. Four of
the six replication studies demonstrated an increased hazard for the allelic effect of
rs3218536, although individual study hazard ratios were not statistically significant. The
pooled analysis of 8,781 breast cancer cases (including 1,414 deaths) showed that overall,
each copy of the minor allele for rs3218536 was associated with a hazard ratio of 1.19
(1.05–1.36), p=0.01, after adjustment for age and study (table 3 and supplementary figure 1).
Similar results were obtained if the analysis was restricted to European subjects [1,381
deaths out of 8,615; HR: 1.19 (1.04–1.37)]. The HR for the combined replication studies
when SBCS data was excluded was 1.15 (1.00–1.33)[p=0.05].
Pooley et al (2008) reported that the rs3218536 SNP was specifically associated with
receptor-positive tumours.[27] Therefore, we explored the hypothesis of a differential
survival effect according to receptor status. However, the effect of rs3218536 on survival in
the pooled dataset did not vary significantly according to ER or PR status (pinteraction=0.16
for PR; pinteraction=0.61 for ER; supplementary table 5).
DISCUSSION
In this study we successfully genotyped a total of 12 tSNPs in the XRCC2 gene and
examined their associations with breast cancer risk and survival in the SBCS. The SNP
rs3218408 was associated with breast cancer susceptibility. A rare haplotype, including the
minor allele at rs3218408, was also identified as associated with breast cancer risk, but this
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result will require very large samples to replicate, given the rarity of the haplotype. SNP
rs3218408 was also associated with breast cancer risk in the UBCS data set. The data were
most consistent with a recessive mode of inheritance.
Four similar candidate gene case-control studies employing tag-SNP approaches have been
published with respect to XRCC2 and breast cancer risk. Han et al. found the OR (95% CI)
for the additive effect of rs3218408 was 0.98 (0.76–1.26) for premenopausal breast cancer
risk in a sample size of 238 cases and 474 controls drawn from the predominantly Caucasian
Nurses Health Study.[28] Using the genotype distributions supplementary to their
publication, we estimated the OR (95% CI) for the recessive effect to be 1.26 (0.68–2.31).
Pharoah et al genotyped the rs3218499 SNP in 2176 cases and 2274 controls from the
SEARCH study.[45] This SNP is correlated with rs3218408 with r2=0.97, and yielded an
OR (95% CI) of 1.14 (0.86–1.50) for the recessive model. Both of the above studies,
together with GWAS data from the CGEMs NHS study, were incorporated into the meta-
analysis shown in figure 2, resulting in an overall recessive OR (95% CI) of 1.33 (1.12–
1.57). In another SEARCH study, Pooley et al genotyped a panel of 8 SNPs in XRCC2, in
2,270 cases and 2,280 controls. However, none of these were any more strongly correlated
to rs3218408 than the rs3218499 SNP included in our meta-analysis. Pooley et al found a
weak protective effect of rs3218536 (R188H), which was most significant in ER and PR
positive tumours.[27] This effect was not seen in our SBCS data, nor was it reproduced in
the large study done by the BCAC,[25] although we did observe a non-significant protective
OR in SBCS receptor positive tumours [OR (95% CI) 0.80 (0.61–1.05); data not shown].
Haiman et al[26] genotyped 24 XRCC2 SNPs, including rs3218408, in a multi-ethnic study
of 2,093 cases and 2,303 controls, and none of the XRCC2 SNPs were associated with
breast cancer under an additive model, although the genotype distributions were not
available to allow assessment of any recessive effects and could therefore not be included in
our meta analysis. The available data suggests a recessive mode of inheritance, although we
are not able to rule out other models. While further studies are required to resolve this issue,
it seems biologically plausible that homozygous deficiency of a protein involved in DNA
repair might be associated with increased cancer risk.
We also examined the XRCC2 SNPs for their associations with overall survival in breast
cancer patients. We observed that two XRCC2 SNPs (rs3218536 and rs3218455) were
statistically associated with survival. These two SNPs are correlated (r2=0.85) and are likely
to be reflecting the same underlying effect. The effect of rs3218536 (R188H) remained
significant in the multivariate analysis after adjustment for age at diagnosis, grade, lymph
node, and tumour size, suggesting it may have an independent role in overall survival.
Our finding of a role for rs3218536 was not in accord with a recently published work, which
found no statistically significant effect of the XRCC2 R188H SNP on breast cancer survival
in 2,270 cases from the SEARCH study.[27] However, our pooled analysis of 7 datasets
from the BCAC, including both the SBCS and a larger set of SEARCH cases (4,234),
provided some support for an association. The minor allele of rs3218536 was associated
with a 19% increased risk of death in a total of 8,781 case subjects (p=0.01). Further
replications are needed to confirm this nominally significant result.
Despite the strength of the use of the large sample sizes, there are some limitations in this
study. The risk association reported here was confined to the meta-analysis of the candidate
gene studies and one available set of GWAS data; further replication by the incorporation of
other relevant genome-wide association data would be beneficial. The use of the UBCS
cases could lead to a biased estimate of risk, since they are drawn from high risk pedigrees.
However, we see no evidence of this, since the estimate of the odds ratio from the meta-
analysis remained the same when the UBCS data was excluded [recessive OR=1.33 (1.11–
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1.59)]. In addition, the inclusion of prevalent cases may potentially bias our estimates of
breast cancer risk and survival if certain genotypes favour long-term survival. However, we
found no evidence that the risk SNP rs3218408 was associated with breast cancer survival,
thus the risk estimate is unlikely to be biased. The inclusion of prevalent cases in the
survival study may lead to bias in HR estimates. To minimise any potential bias, we
employed the left-truncated Cox model. The use of this model with prevalent cases yields
the same HR estimates as those found when only incident cases are included. [44]
Due to the role of BRCA1 and BRCA2 in DNA repair, a large number of candidate gene
studies of DNA repair genes have been carried out, although few have been conclusively
replicated. Genome-wide association and sequencing studies have however provided support
for a role for DNA repair genes in breast cancer risk. RAD51L1 (RAD51B) is a member of
the RAD51 family of DNA double strand break repair proteins and is associated with risk,
[46] and a number of proteins that interact with BRCA1 and BRCA2, such as PALB2 and
BRIP1, have been shown to be mutated, albeit rarely, in familial breast cancers (reviewed in
[47]). More recently a variant near the MERIT40 gene, whose protein is a component of the
BRCA1-A complex, has been shown to act as a modifier of risk in BRCA1 mutation
carriers,[48] and to affect ovarian cancer risk.[49]
In conclusion, our study provides evidence supporting an association of the XRCC2
rs3218408 SNP with the risk of breast cancer. If further replicated, data for this SNP could
be incorporated into risk models with other validated SNPs. Beyond this single SNP result, a
significant haplotype association, incorporating the minor allele at this SNP, was also
identified. However, much larger studies of multiple SNPs will be required to further
investigate this potentially large effect. With respect to overall survival, we observed an
association with the XRCC2 rs3218536 (R188H) SNP. An association with survival has also
been reported for this SNP in pancreatic cancer patients, especially in those who received
both chemotherapy and X-ray therapy.[50] With the observation that rs3218536 variant cells
show increased resistance to cisplatin treatments compared to wild-type cells,[51] future
studies are needed to evaluate rs3218536 in the context of chemotherapy, to determine
whether there may be implications for treating breast cancer.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Negative log10 p values for additive, codominant, dominant and recessive models for the
XRCC2 SNPs in the SBCS. For each model the upper dash line represents the Bonferroni
threshold of 4.2×10−3 and the lower dash line represents the nominal significant value of
0.05. Chromosome positions are given in Mb and refer to NCBI build36/hg18 of the human
genome
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Figure 2.
Meta-analysis of the association of rs3218408 with breast cancer risk. Due to the lack of
rs3218408 genotype data in the SEARCH study, data for the highly correlated SNP,
rs3218499, was used. Fixed effect estimates are shown, with p value for homogeneity in
parenthesis
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Table 1
Estimated breast cancer odds ratios (ORs) for haplotypes in the XRCC2 gene in SBCS
Haplotypes* Case frequency (%) Control frequency (%) OR (95% CI)
Block1†
  1-1-2-1-1 987.98 (43.68) 1024.45 (44.62) 1
  1-1-1-1-2 524.75 (23.2) 510.97 (22.25) 1.07 (0.92–1.24)
  1-1-1-1-1 393.56 (17.4) 368.08 (16.03) 1.12 (0.94–1.33)
  1-2-1-1-1 178.07 (7.87) 203.09 (8.85) 0.9 (0.72–1.13)
  2-1-1-1-1 85.94 (3.8) 93.79 (4.09) 0.94 (0.69–1.3)
  1-1-1-2-1 80.14 (3.54) 80.29 (3.5) 1.03 (0.75–1.42)
  rare haplotypes 11.57 (0.51) 15.33 (0.67) 0.77 (0.34–1.77)
Block2‡
  1-1-1-1-1-1-2 959.74 (42.43) 1004.07 (43.73) 1
  1-1-1-2-1-2-1 506.51 (22.39) 501.74 (21.85) 1.05 (0.90–1.23)
  1-1-1-1-2-2-1 230.88 (10.21) 221.96 (9.67) 1.10 (0.89–1.35)
  2-1-1-1-1-2-1 175.95 (7.78) 197.57 (8.60) 0.91 (0.73–1.13)
  1-2-2-1-1-1-1 102.96 (4.55) 108.17 (4.71) 0.99 (0.73–1.33)
  1-1-2-1-1-1-1 95.57 (4.23) 96.37 (4.20) 1.06 (0.76-1.47)
  1-1-1-1-1-2-1 85.98 (3.8) 99.69 (4.34) 0.89 (0.64–1.23)
  rare haplotypes 104.42 (4.61) 66.43 (2.89) 1.68 (1.21–2.32)
20.24 (0.89) 4.56 (0.20) 6.50 (1.88–22.48)
84.17 (3.72) 61.87 (2.69) 1.37 (0.96–1.97)
*1 represents the common allele and 2 the minor allele. “Rare haplotypes” indicates those with frequency below 1%.
†
the order of SNPs in block 1 are rs3218556, rs3218536, rs3218534, rs3218501, and rs3218499.
‡
The order of SNPs in block 2 are rs3218455, rs3111465, rs3094406, rs3218408, rs3218400, rs2106776, and rs3218374.
§
the bracket indicates the subdivision of the rare haplotypes into 1112112 and the rest.
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Table 2
Associations of XRCC2 SNPs with survival in SBCS breast cancer patients
SNPs Genotypes* No. Total/Death† Log-rank p value aHR‡ (95% CI)
rs3218556 CC 721/178 0.1295 1
CT 63/20 1.63 (0.97–2.75)
rs3218536 GG 652/165 4×10−6 1
GA 110/30 1.19 (0.76–1.89)
AA 7/5 4.26 (1.69–10.72)
Per A allele 1.48 (1.04–2.13)
rs3218534 CC 259/71 0.0224 1
CT 396/93 0.60 (0.42–0.85)
TT 150/41 0.74 (0.46–1.19)
Per T allele 0.79 (0.62–1.01)
rs3218501 CC 721/193 0.2316 1
CG+GG 54/8 0.60 (0.26–1.35)
rs3218499 GG 445/122 0.7159 1
GC 284/68 0.87 (0.61–1.24)
CC 39/9 0.80 (0.35–1.84)
rs3218455 TT 648/165 2×10−6 1
TC 113/29 1.16 (0.73–1.83)
CC 11/7 3.86 (1.76–8.47)
Per C allele 1.51 (1.08–2.10)
rs3111465 GG 600/155 0.7031 1
GA+AA 51/12 0.95 (0.48–1.88)
rs3094406 CC 508/130 0.1816 1
CG+GG 115/36 1.49 (0.97–2.26)
rs3218408 TT 442/121 0.8815 1
TG 248/61 0.90 (0.62–1.30)
GG 66/16 0.87 (0.47–1.63)
rs3218400 CC 586/155 0.6323 1
CA+AA 190/47 1.04 (0.71–1.51)
rs2106776 CC 177/53 0.1076 1
CT 313/69 0.79 (0.51–1.22)
TT 128/38 1.26 (0.77–2.06)
rs3218374 CC 235/67 0.0248 1
CG 365/89 0.59 (0.41–0.86)
GG 157/42 0.78 (0.49–1.24)
Per G allele 0.82 (0.64–1.05)
*genotypes were grouped if the number of deaths were less than 3
†
total numbers differ between SNPs due to missing genotypes
‡
adjusted for age (continuous variable) and left-censoring at recruitment
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Table 3
Association of rs3218536 with breast cancer survival by study*
Study No. Total No. Deaths HR† (95% CI) p value
ABCFS 1223 270 1.14 (0.81–1.60) 0.45
CNIO-BC
S 190 6 1.03 (0.14–7.67) 0.97
HABCS 598 86 0.80 (0.39–1.62) 0.53
PBCS 1507 209 1.21 (0.83–1.77) 0.33
SBCS 707 139 1.48 (1.04–2.13) 0.03
SEARCH 4234 700 1.16 (0.97–1.39) 0.11
USRTS 322 4 1.72 (0.17–17.86) 0.65
Pooled 8781 1414 1.19 (1.05–1.36) 0.01
*
the number of cases do not correspond to supplementary table 1 due to some missing genotype data.
†
adjusted for age and left-censoring at recruitment; pooled estimate stratified by study
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